Aardvark Therapeutics, Inc.
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
AARD | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 4370 LA JOLLA VILLAGE DRIVE, 92122 SAN DIEGO
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapies to inhibit hunger and treat metabolic diseases. Its lead investigational compound, ARD-101, is an oral drug designed to act locally in the digestive tract. The therapy works by activating bitter taste receptors (TAS2Rs) to stimulate the release of satiety hormones, which send signals to the brain to suppress appetite. The company's goal is to become a leader in treating hunger, with primary applications in hyperphagia associated with rare diseases, as well as obesity and related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aardvark Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aardvark Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aardvark Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
